New research shows discontinuing Wegovy/Ozempic leads to weight regain and a 22% higher heart attack/stroke risk, strengthening the case for lifelong use.

A significant new study provides a powerful medical and commercial argument for Novo Nordisk. The research indicates that discontinuing GLP-1 agonist therapies, such as Wegovy or Ozempic, is linked not only to weight regain but also to a substantially increased risk of serious cardiovascular events like heart attacks and strokes.

Compelling Clinical Evidence for Continued Treatment

Published in the journal BMJ Medicine, the research analyzed health records from more than 333,000 U.S. veterans diagnosed with type-2 diabetes over a three-year period. The findings were clear: cardiovascular risk begins to rise measurably within just six months of stopping treatment. Patients who halted their GLP-1 medication for two years faced a 22% higher risk of major adverse cardiac events compared to those who continued therapy. Conversely, the group that maintained treatment saw their risk reduced by 18%.

For Novo Nordisk, this data underscores a clinical rationale for lifelong medication use. A common challenge has been patient discontinuation due to cost or side effects. These compelling results could encourage physicians to emphasize adherence more strongly, potentially translating into more stable, recurring revenue streams for the pharmaceutical giant.

Navigating Market Headwinds and Competition

This positive clinical news arrives amidst a challenging commercial landscape. The patent protection for semaglutide, the active ingredient in several Novo Nordisk blockbusters, is set to expire in India on March 20, 2026. This is expected to prompt generic drug manufacturers to quickly enter the price-sensitive market, increasing margin pressure.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Novo Nordisk is executing a multi-pronged strategy in response. The company is aggressively expanding its global production capacity to meet soaring demand. It is also advancing the development of oral formulations, such as Amycretin, which may improve patient convenience. Furthermore, a collaboration with the telemedicine platform Hims & Hers aims to streamline U.S. patient access to authentic Novo Nordisk products, steering them away from unregulated copycat drugs.

The effectiveness of these initiatives—the production ramp-up and the new distribution partnership—in offsetting the financial impact of the Indian patent expiration will become clearer in upcoming quarterly reports. The company’s strategic moves are explicitly designed to counter this anticipated competitive pressure.

Ad

Novo Nordisk Stock: New Analysis – 19 March

Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis…